Incyte Corp
(BSP:I1NC34)
R$
221.1
0 (0%)
Market Cap: 85.19 Bil
Enterprise Value: 75.12 Bil
PE Ratio: 541.07
PB Ratio: 4.61
GF Score: 77/100 
Incyte Corp at RBC Capital Markets Healthcare Conference Transcript
May 21, 2019 / 02:30PM GMT
Brian Corey Abrahams
RBC Capital Markets, LLC, Research Division - Senior Analyst
We're really pleased to have our next presenting company here, Incyte, represented by their President and CEO, Hervé Hoppenot. Hervé?
HervÃ;Hoppenot
Incyte Corporation - Chairman, President & CEO
© -
Thank you. Thank you for inviting us.
Brian Corey Abrahams
RBC Capital Markets, LLC, Research Division - Senior Analyst
Thank you so much. Really appreciate it. A lot to cover. So yes, just -- let's get started.
Questions & Answers
Brian Corey Abrahams;HervÃ;Hoppenot
RBC Capital Markets, LLC, Research Division - Senior Analyst;
Maybe kicking off with GVHD since that's the next potential data point and catalyst that we're going to hear about. Can you -- maybe you could tell us a little bit more in terms of background on the GVHD program. And in particular, the Jakafi PDUFA date is coming up very soon push back to...
©
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers